Cannabis Europa is excited to announce Dragonfly Biosciences as a Bronze Partner for our London conference this June at the Southbank Centre.
Dragonfly Biosciences is Europe’s largest and leading producer of cannabidiol (CBD) and cannabis-derived extracts. After rapid growth in the past two years, it now boasts a head office in London, farms and formulation facilities in Bulgaria, and partner companies in Poland, Canada and Malta. A seed-to-sale producer, Dragonfly’s reach is bolstered by 650 hectares of organically certified, fully irrigated farmland – a capacity soon to rise.
Cannabis Europa is the foremost arena to share knowledge and shape the future of cannabis policy in Europe, dedicated to creating a space for conversation on most pressing issues for European businesses. After a recent European Commission regulation on Novel Foods introduced a level of uncertainty for EU businesses working with CBD in foods and cosmetics, Dragonfly’s expertise will be key for those looking to navigate the complicated regulations.
Is CBD a food, medicine, or both? At Cannabis Europa, leaders will gather to delve into the most acute challenges in CBD production and regulation in Europe, a continent traditionally strong in hemp cultivation and export. Legal experts, stakeholders and political actors with the inside track on developing regulatory processes will discuss solutions to the opaque and convoluted legal status of cannabidiol in Europe.
“Dragonfly is delighted to bring its expertise in CBD business and policy to Cannabis Europa. The conference provides an important platform for a diverse range of authoritative voices in the field to come together. Such discussions are an excellent starting point for the birth of a sustainable and transparent industry, and we’re really excited to be a part of that.” Hannah Skingle, Chief Operating Officer, Dragonfly Biosciences
Cannabis Europa London attendees will hear about the implications of the EU’s Novel Foods Regulations for companies looking to include CBD in foods and food supplements, and the possible effects of blurred lines between medical and wellness CBD, as well as ways to increase government-level understanding of cannabidiol. Join the conversation this 24-25th June. Tickets available now.